Mirati Therapeutics

Cancer is unique. Cancer is smart. Cancer is specific. Treatment should be too. Mirati is at the forefront of precision medicine -- developing genetically-targeted oncology therapeutics for carefully selected groups of patients most likely to benefit from treatment. Mirati’s approach to precision medicine combines three critical factors. Most importantly, Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Mirati combines the therapeutic potential of these assets with its creative and agile clinical development strategies focused on identifying and treating patients whose tumors carry the drivers of disease. Finally, this process is led and executed by a highly accomplished precision medicine team, with a track record of bringing breakthrough therapies with accelerated development paths to market.
Type
Public
HQ
San Diego, US
Employees
38 (est)

Mirati Therapeutics Locations

San Diego, US

Mirati Therapeutics Metrics

Mirati Therapeutics Summary

Market capitalization

$101 M

Closing share price

$5.25

Mirati Therapeutics Market Value History

Mirati Therapeutics News

Mirati Therapeutics Company Life

You may also be interested in